Achondroplasia clinical trials at UCSF
6 in progress, 1 open to eligible people
Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)
open to eligible people ages 30 months to 10 years
This is a long-term, multi-center, observational study in children 2.5 to 10 years with achondroplasia (ACH). The objective is to evaluate growth, ACH-related medical complications and treatments of study participants. No study medication will be administered.
Oakland, California and other locations
A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia
Sorry, accepting new patients by invitation only
Study 111-206 is a Phase 2 randomized, double-blind, placebo-controlled clinical trial of BMN 111 in infants and young children with a diagnosis of Achondroplasia.
Oakland, California and other locations
A Multicenter, Multinational Clinical Assessment Study for Pediatric Patients With Achondroplasia
Sorry, accepting new patients by invitation only
Multicenter, multinational study to collect consistent baseline growth measurements on pediatric patients with Achondroplasia being considered for subsequent enrollment in future studies sponsored by BioMarin. No study drug is administered.
Oakland, California and other locations
A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)
Sorry, in progress, not accepting new patients
This is a Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children with Achondroplasia. The primary objective is to evaluate the long-term safety and tolerability of daily SC injections of BMN 111 in children with ACH who have completed two years of treatment in the 111-202 study.
Oakland, California and other locations
An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia
Sorry, accepting new patients by invitation only
This is a Phase 2, open-label multi-center long-term extension study, with approximately 70 subjects, to evaluate the safety and efficacy of BMN111 in children with Achondroplasia until subjects reach near-adult final height. Eligible subjects will have completed 1 year of BMN111 or placebo treatment in the 111-206 study and once enrolled in the 111-208 extension study will receive a daily dose of BMN111 by subcutaneous injection according to their age as determined by 111-206.
Oakland, California and other locations
An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia
Sorry, in progress, not accepting new patients
The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia
Oakland, California and other locations
Last updated: